Advanced Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
- Published Date : November 25, 2024
- Updated On : August 4, 2025
- Pages : 159
Advanced Parkinson’s Disease Market Outlook
Thelansis’s “Advanced Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Parkinson’s Disease Overview
Advanced Parkinson’s Disease is a late-stage progression of this neurodegenerative disorder, with a multifaceted interplay of motor and non-motor impairment that severely impairs quality of life and daily activities. With additional loss of dopaminergic neurons in the substantia nigra, patients have more severe motor fluctuations, dyskinesias, freezing of gait, postural instability, and risk of falls, usually making them dependent on caregivers. Non-motor features—cognitive impairment, hallucinations, autonomic dysfunction, sleep disturbances, and mood disorders—take over and become refractory to conventional therapies, making treatment more difficult. Levodopa is still the mainstay of therapy, but decreasing efficacy and side effects at advanced stages make it necessary to use adjunctive measures, such as dopamine agonists, MAO-B inhibitors, and device-based approaches like DBS or levodopa-carbidopa intestinal gel infusion. Multidisciplinary care in neurology, physical therapy, psychiatry, and palliative care is needed to meet the changing needs of patients and caregivers. The course of the disease is very unpredictable, and goal-oriented individualized treatment is essential to preserve autonomy, avoid complications, and preserve dignity in the face of progressive impairment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced Parkinson’s Disease Market Outlook
Thelansis’s “Advanced Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Parkinson’s Disease Overview
Advanced Parkinson’s Disease is a late-stage progression of this neurodegenerative disorder, with a multifaceted interplay of motor and non-motor impairment that severely impairs quality of life and daily activities. With additional loss of dopaminergic neurons in the substantia nigra, patients have more severe motor fluctuations, dyskinesias, freezing of gait, postural instability, and risk of falls, usually making them dependent on caregivers. Non-motor features—cognitive impairment, hallucinations, autonomic dysfunction, sleep disturbances, and mood disorders—take over and become refractory to conventional therapies, making treatment more difficult. Levodopa is still the mainstay of therapy, but decreasing efficacy and side effects at advanced stages make it necessary to use adjunctive measures, such as dopamine agonists, MAO-B inhibitors, and device-based approaches like DBS or levodopa-carbidopa intestinal gel infusion. Multidisciplinary care in neurology, physical therapy, psychiatry, and palliative care is needed to meet the changing needs of patients and caregivers. The course of the disease is very unpredictable, and goal-oriented individualized treatment is essential to preserve autonomy, avoid complications, and preserve dignity in the face of progressive impairment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)